02/25/22 REVISOR AGW/LN 22-06638 as introduced

SENATE STATE OF MINNESOTA NINETY-SECOND SESSION

S.F. No. 3940

(SENATE AUTHORS: DUCKWORTH, Benson and Rosen)

DATE 03/14/2022 5305 Introduction and first reading Referred to Health and Human Services Finance and Policy 03/21/2022 5483 Author added Rosen Comm report: To pass as amended and re-refer to Finance

1.1 A bill for an act

1.6

1.10

1.11

1.12

1.13

1.14

1.15

1.16

1.17

1.18

1.19

1.20

1.21

1.22

1.23

relating to health occupations; expanding licensed pharmacist authority to initiate, order, and administer vaccines and certain medical and laboratory tests; requiring coverage under medical assistance; amending Minnesota Statutes 2020, sections 1.5 151.01, subdivision 27; 256B.0625, by adding a subdivision.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

- 1.7 Section 1. Minnesota Statutes 2020, section 151.01, subdivision 27, is amended to read:
- Subd. 27. **Practice of pharmacy.** "Practice of pharmacy" means:
- (1) interpretation and evaluation of prescription drug orders;
 - (2) compounding, labeling, and dispensing drugs and devices (except labeling by a manufacturer or packager of nonprescription drugs or commercially packaged legend drugs and devices);
 - (3) participation in clinical interpretations and monitoring of drug therapy for assurance of safe and effective use of drugs, including the performance of ordering and performing laboratory tests that are waived under the federal Clinical Laboratory Improvement Act of 1988, United States Code, title 42, section 263a et seq., provided that a pharmacist may interpret the results of laboratory tests but may modify A pharmacist may collect specimens, interpret results, notify the patient of results, and refer patients to other health care providers for follow-up care and may initiate, modify, or discontinue drug therapy only pursuant to a protocol or collaborative practice agreement. A pharmacist may delegate the authority to administer tests under this clause to a pharmacy technician or pharmacy intern;
 - (4) participation in drug and therapeutic device selection; drug administration for first dosage and medical emergencies; intramuscular and subcutaneous administration used for

Section 1.

the treatment of alcohol or opioid dependence; drug regimen reviews; and drug or drug-related research;

2.1

2.2

2.3

2.4

2.5

2.6

2.7

2.8

2.9

2.10

2.11

2.12

2.13

2.14

2.15

2.16

2.17

2.18

2.19

2.20

2.21

2.22

2.23

2.24

2.25

2.26

- (5) drug administration, through intramuscular and subcutaneous administration used to treat mental illnesses as permitted under the following conditions:
- (i) upon the order of a prescriber and the prescriber is notified after administration is complete; or
- (ii) pursuant to a protocol or collaborative practice agreement as defined by section 151.01, subdivisions 27b and 27c, and participation in the initiation, management, modification, administration, and discontinuation of drug therapy is according to the protocol or collaborative practice agreement between the pharmacist and a dentist, optometrist, physician, podiatrist, or veterinarian, or an advanced practice registered nurse authorized to prescribe, dispense, and administer under section 148.235. Any changes in drug therapy or medication administration made pursuant to a protocol or collaborative practice agreement must be documented by the pharmacist in the patient's medical record or reported by the pharmacist to a practitioner responsible for the patient's care;
- (6) participation in administration of influenza vaccines and initiating, ordering, and administering vaccines authorized or approved by the United States Food and Drug Administration related to COVID-19 or SARS-CoV-2 to all eligible individuals six three years of age and older and all other vaccines to patients 13 years of age and older by written protocol with a physician licensed under chapter 147, a physician assistant authorized to prescribe drugs under chapter 147A, or an advanced practice registered nurse authorized to prescribe drugs under section 148.235, provided that according to the federal Advisory Committee on Immunization Practices schedules. A pharmacist may delegate the authority to administer vaccines under this clause to a pharmacy technician or pharmacy intern who has completed training in vaccine administration if:
 - (i) the protocol includes, at a minimum:
- 2.27 (A) the name, dose, and route of each vaccine that may be given;
- 2.28 (B) the patient population for whom the vaccine may be given;
- 2.29 (C) contraindications and precautions to the vaccine;
- 2.30 (D) the procedure for handling an adverse reaction;
- 2.31 (E) the name, signature, and address of the physician, physician assistant, or advanced practice registered nurse;

Section 1. 2

(F) a telephone number at which the physician, physician assistant, or advanced practice 3.1 registered nurse can be contacted; and 3.2 (G) the date and time period for which the protocol is valid; 3.3 (ii) (i) the pharmacist has and the pharmacy technician or pharmacy intern have 3.4 successfully completed a program approved by the Accreditation Council for Pharmacy 3.5 Education (ACPE) specifically for the administration of immunizations or a program 3.6 approved by the board; 3.7 (iii) (ii) the pharmacist utilizes and the pharmacy technician or pharmacy intern utilize 3.8 the Minnesota Immunization Information Connection to assess the immunization status of 3.9 individuals prior to the administration of vaccines, except when administering influenza 3.10 vaccines to individuals age nine three and older; 3.11 (iv) (iii) the pharmacist reports the administration of the immunization to the Minnesota 3.12 Immunization Information Connection: and 3.13 (v) the pharmacist complies with guidelines for vaccines and immunizations established 3.14 by the federal Advisory Committee on Immunization Practices, except that a pharmacist 3.15 does not need to comply with those portions of the guidelines that establish immunization 3.16 schedules when administering a vaccine pursuant to a valid, patient-specific order issued 3.17 by a physician licensed under chapter 147, a physician assistant authorized to prescribe 3.18 drugs under chapter 147A, or an advanced practice registered nurse authorized to prescribe 3.19 drugs under section 148.235, provided that the order is consistent with the United States 3.20 Food and Drug Administration approved labeling of the vaccine; 3.21 (iv) if the patient is 18 years of age or younger, the pharmacist, pharmacy technician, 3.22 or pharmacy intern informs the patient and any adult caregiver accompanying the patient 3.23 of the importance of a well-child visit with a pediatrician or other licensed primary care 3.24 provider; and 3.25 (v) in the case of a pharmacy technician administering vaccinations while being 3.26 supervised by a licensed pharmacist: 3.27 (A) the pharmacist is readily and immediately available to the immunizing pharmacy 3.28 technician; 3.29 (B) the pharmacy technician has a current certificate in basic cardiopulmonary 3.30 resuscitation; and 3.31

Section 1. 3

REVISOR

4.1	(C) the pharmacy technician has completed a minimum of two hours of ACPE-approved,
4.2	immunization-related continuing pharmacy education as part of the pharmacy technician's
4.3	two-year continuing education schedule;
4.4	(7) participation in the initiation, management, modification, and discontinuation of
4.5	drug therapy according to a written protocol or collaborative practice agreement between:
4.6	(i) one or more pharmacists and one or more dentists, optometrists, physicians, podiatrists,
4.7	or veterinarians; or (ii) one or more pharmacists and one or more physician assistants
4.8	authorized to prescribe, dispense, and administer under chapter 147A, or advanced practice
4.9	registered nurses authorized to prescribe, dispense, and administer under section 148.235.
4.10	Any changes in drug therapy made pursuant to a protocol or collaborative practice agreement
4.11	must be documented by the pharmacist in the patient's medical record or reported by the
4.12	pharmacist to a practitioner responsible for the patient's care;
4.13	(8) participation in the storage of drugs and the maintenance of records;
4.14	(9) patient counseling on therapeutic values, content, hazards, and uses of drugs and
4.15	devices;
4.16	(10) offering or performing those acts, services, operations, or transactions necessary
4.17	in the conduct, operation, management, and control of a pharmacy;
4.18	(11) participation in the initiation, management, modification, and discontinuation of
4.19	therapy with opiate antagonists, as defined in section 604A.04, subdivision 1, pursuant to:
4.20	(i) a written protocol as allowed under clause (7); or
4.21	(ii) a written protocol with a community health board medical consultant or a practitioner
4.22	designated by the commissioner of health, as allowed under section 151.37, subdivision 13;
4.23	and
4.24	(12) prescribing self-administered hormonal contraceptives; nicotine replacement
4.25	medications; and opiate antagonists for the treatment of an acute opiate overdose pursuant
4.26	to section 151.37, subdivision 14, 15, or 16.
4.27	Sec. 2. Minnesota Statutes 2020, section 256B.0625, is amended by adding a subdivision
4.28	to read:
4.29	Subd. 13k. Vaccines and laboratory tests provided by pharmacists. (a) Medical
4.30	assistance covers vaccines initiated, ordered, or administered by a licensed pharmacist,
4.31	according to the requirements of section 151.01, subdivision 27, clause (6), at no less than

Sec. 2. 4

5.1	the rate for which the same services are covered when provided by any other licensed
5.2	practitioner.
5.3	(b) Medical assistance covers laboratory tests ordered and performed by a licensed
5.4	pharmacist, according to the requirements of section 151.01, subdivision 27, clause (3), at
5.5	no less than the rate for which the same services are covered when provided by any other
5.6	licensed practitioner.
5.7	EFFECTIVE DATE. This section is effective January 1, 2023, or upon federal approval,
5.8	whichever is later. The commissioner of human services shall notify the revisor of statutes
5.9	when federal approval is obtained.

AGW/LN

22-06638

as introduced

02/25/22

REVISOR

Sec. 2. 5